Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
November 16, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo...
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
November 14, 2022 08:30 ET
|
Agenus Inc.
Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC)Initiated Phase 2 ACTIVATE trials of...
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
November 08, 2022 08:00 ET
|
Agenus Inc.
Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingInitiated Phase 2...
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
October 25, 2022 08:30 ET
|
Agenus Inc.
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
October 13, 2022 08:32 ET
|
Agenus Inc.
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe disease...
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
October 12, 2022 08:00 ET
|
Agenus Inc.
Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1)...
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
October 05, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022 08:00 ET
|
Agenus Inc.
Clinical data in nine cancer indications from trial with 264 patients accruedPlenary discussion relating to expansion cohorts represent heavily pretreated patientsAdditional SITC presentations cover...
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
September 12, 2022 08:30 ET
|
Agenus Inc.
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust...
Agenus Makes Senior Regulatory and Clinical Appointments
September 12, 2022 08:30 ET
|
Agenus Inc.
Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 ...